文献速递类风湿关节炎

Filgotinib对比安慰剂或阿达木单抗治疗甲氨蝶呤应答不足的类风湿关节炎:III期随机临床试验

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
PubMed 文献 · Ann Rheum Dis · 2021-01-27

这项52周III期随机双盲试验纳入1755例对甲氨蝶呤应答不足的活动性类风湿关节炎患者,评估口服Filgotinib 200mg或100mg对比安慰剂或阿达木单抗的疗效与安全性。第12周ACR20应答率FIL200组76.6%、FIL100组69.8%,均显著高于安慰剂组49.9%。FIL200在DAS28-CRP≤3.2方面非劣于阿达木单抗,FIL100未达非劣效。

要点

  • FIL200和FIL100第12周ACR20均显著优于安慰剂,治疗差异分别为26.7%和19.9%。
  • FIL200在DAS28-CRP≤3.2方面非劣于阿达木单抗,FIL100未达非劣效。
  • Filgotinib改善体征症状、身体功能和结构损伤,安全性各活性治疗组相当。

核心结论

  • Filgotinib改善对甲氨蝶呤应答不足的类风湿关节炎患者的体征症状、身体功能并抑制影像学进展,耐受性良好。
  • FIL200在DAS28-CRP≤3.2方面非劣于阿达木单抗,FIL100未达非劣效。

研究设计与样本

  • 52周多中心、双盲、安慰剂对照和活性对照III期试验,患者按3:3:2:3随机分配。
  • 1755例活动性类风湿关节炎且对甲氨蝶呤应答不足的患者随机接受FIL200、FIL100、皮下阿达木单抗40mg每两周一次或安慰剂(至第24周),均联用稳定每周背景甲氨蝶呤。
  • 主要终点为第12周达到ACR20应答的患者比例。

主要发现

  • 第12周ACR20应答率FIL200组76.6%、FIL100组69.8%、安慰剂组49.9%。
  • FIL200对比安慰剂的治疗差异(95%CI)为26.7%(20.6%至32.8%),FIL100为19.9%(13.6%至26.2%),均p<0.001。
  • Filgotinib在评估类风湿关节炎体征症状、身体功能和结构损伤的关键次要终点上优于安慰剂。
  • FIL200在DAS28-CRP≤3.2方面非劣于阿达木单抗(p<0.001),FIL100未达非劣效。
  • 各活性治疗组间不良事件和实验室异常相当。

关键数值与推荐

  • 主要终点第12周ACR20应答率:FIL200组76.6%,FIL100组69.8%,安慰剂组49.9%。
  • FIL200对比安慰剂治疗差异26.7%(95%CI 20.6%至32.8%),FIL100对比安慰剂19.9%(95%CI 13.6%至26.2%),均p<0.001。
  • FIL200在DAS28-CRP≤3.2方面非劣于阿达木单抗(p<0.001)。

临床怎么用

  • 对甲氨蝶呤应答不足的活动性类风湿关节炎患者,Filgotinib 200mg每日一次可显著提高第12周ACR20应答率。
  • FIL200可作为对甲氨蝶呤应答不足患者的一种口服治疗选择,其在DAS28-CRP≤3.2方面非劣于阿达木单抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). METHODS: This 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III trial evaluated once-daily oral filgotinib in patients with RA randomised 3:3:2:3 to filgotinib 200 mg (FIL200) or filgotinib 100 mg (FIL100), subcutaneous adalimumab 40 mg biweekly, or placebo (through week 24), all with stable weekly background MTX. The primary endpoint was the proportion of patients achieving 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Additional efficacy outcomes were assessed sequentially. Safety was assessed from adverse events and laboratory abnormalities. RESULTS: The proportion of patients (n=1755 randomised and treated) achieving ACR20 at week 12 was significantly higher for FIL200 (76.6%) and FIL100 (69.8%) versus placebo (49.9%; treatment difference (95% CI), 26.7% (20.6% to 32.8%) and 19.9% (13.6% to 26.2%), respectively; both p<0.001). Filgotinib was superior to placebo in key secondary endpoints assessing RA signs and symptoms, physical function and structural damage. FIL200 was non-inferior to adalimumab in terms of Disease Activity Score in 28 joints with C reactive protein ≤3.2 at week 12 (p<0.001); FIL100 did not achieve non-inferiority. Adverse events and laboratory abnormalities were comparable among active treatment arms. CONCLUSIONS: Filgotinib improved RA signs and symptoms, improved physical function, inhibited radiographic progression and was well tolerated in patients with RA with inadequate response to MTX. FIL200 was non-inferior to adalimumab. TRIAL REGISTRATION NUMBER: NCT02889796.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021. PMID: 33504485. doi:10.1136/annrheumdis-2020-219214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。